Molecular targeted therapy of BRAF-mutant colorectal cancer - PubMed (original) (raw)
Review
Molecular targeted therapy of _BRAF_-mutant colorectal cancer
Michel Ducreux et al. Ther Adv Med Oncol. 2019.
Abstract
Over the past two decades, the molecular characterization of metastatic colorectal cancer (mCRC) has been revolutionized by the routine implementation of RAS and BRAF tests. As a result, it is now known that patients with mCRC harboring BRAF mutations experience a poor prognosis. Although it accounts for only 10% of mCRC, this group is heterogeneous; only the _BRAF-_V600E mutation, also observed in melanoma, is associated with a very poor prognosis. In terms of treatment, these patients do not benefit from therapeutics targeting the epidermal growth factor receptor (EGFR). In first-line chemotherapy, there are two main options; the first one is to use a triple chemotherapy combination of 5-fluorouracil, irinotecan, and oxaliplatin, with the addition of bevacizumab, because post hoc analysis of randomized trials have reported interesting results. The other option is to use double chemotherapy plus bevacizumab, since anti-EGFR seems to have modest activity in these patients. Only a small percentage of patients who experience failure of this first-line treatment receive second-line treatment. Monotherapy with BRAF inhibitors has failed in this setting, and different combinations have also been tested. Using the rationale that BRAF inhibitor monotherapy fails due to feedback activation of the EGFR pathway, BRAF inhibitors have been combined with anti-EGFR agents plus or minus MEK inhibitors; however, the results did not live up to the hopes raised by the concept. To date, the best results in second-line treatment have been obtained with a combination of vemurafenib, cetuximab, and irinotecan. Despite these advances, further improvements are needed.
Keywords: BRAF inhibitors; BRAF mutation; chemotherapy; colorectal cancer.
Conflict of interest statement
Conflict of interest statement: The authors declare the following conflicts of interest: MD: Personal fees: MSD, Merck Serono, Roche, Bayer, Ipsen, Lilly, Servier, AMGEN, HalioDX, Sanofi; Travel, accommodation, expenses: Roche, MSD, AMGEN. AC: Personal fees: AMGEN PLP: Travel accommodation, expenses: Roche, MSD. CS: None. AEH: Personal fees: Merck Serono, AMGEN, Gribstone Oncology; Travel, accommodation, expenses: AMGEN, SERVIER. PD: None. ES: Personal fees: Sanofi, Bayer, Servier, Pfizer, Novartis, Roche, AMGEN, Merck. VB: Personal fees: Bayer, Merck Serono, Roche, Sanofi, Ipsen; Travel, accommodation: Bayer, Merck Serono, Roche. DM: Personal fees: AMGEN, Bayer, Merck, Merck Serono, Roche, Sanofi, Servier, Shire, HalioDx, Agios. Nonfinancial support: AMGEN, Bayer, Merck, Merck Serono, Roche, Sanofi, Servier. MG: None.
Figures
Figure 1.
The RAS–RAF–MEK–ERK cellular signaling cascade.
Figure 2.
BRAF schematic primary structure, showing functional domains. AL, activation loop; CL, catalytic loop; CR, conserved region; CRD, cysteine-rich domain; KD, kinase domain; P-L, phosphate-binding loop; RBD, RAS-binding domain.
Similar articles
- Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
Grothey A, Fakih M, Tabernero J. Grothey A, et al. Ann Oncol. 2021 Aug;32(8):959-967. doi: 10.1016/j.annonc.2021.03.206. Epub 2021 Apr 7. Ann Oncol. 2021. PMID: 33836264 Review. - FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of _BRAF_V600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.
Stintzing S, Heinrich K, Tougeron D, Modest DP, Schwaner I, Eucker J, Pihusch R, Stauch M, Kaiser F, Kahl C, Karthaus M, Müller C, Burkart C, Reinacher-Schick A, Kasper-Virchow S, Fischer von Weikersthal L, Krammer-Steiner B, Prager GW, Taieb J, Heinemann V. Stintzing S, et al. J Clin Oncol. 2023 Sep 1;41(25):4143-4153. doi: 10.1200/JCO.22.01420. Epub 2023 Jun 23. J Clin Oncol. 2023. PMID: 37352476 Clinical Trial. - Complete response with fluorouracil and irinotecan with a BRAFV600E and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report.
Wang Z, Dai WP, Zang YS. Wang Z, et al. Onco Targets Ther. 2019 Jan 8;12:443-447. doi: 10.2147/OTT.S180845. eCollection 2019. Onco Targets Ther. 2019. PMID: 30662270 Free PMC article. - Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study.
Martinelli E, Cremolini C, Mazard T, Vidal J, Virchow I, Tougeron D, Cuyle PJ, Chibaudel B, Kim S, Ghanem I, Asselain B, Castagné C, Zkik A, Khan S, Arnold D. Martinelli E, et al. ESMO Open. 2022 Dec;7(6):100603. doi: 10.1016/j.esmoop.2022.100603. Epub 2022 Nov 8. ESMO Open. 2022. PMID: 36368253 Free PMC article. - [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version].
Hummel M, Hegewisch-Becker S, Neumann J, Vogel A. Hummel M, et al. Pathologe. 2021 Nov;42(6):578-590. doi: 10.1007/s00292-021-00942-9. Epub 2021 May 6. Pathologe. 2021. PMID: 33956173 Free PMC article. Review. German.
Cited by
- Differential contribution for ERK1 and ERK2 kinases in BRAFV600E-triggered phenotypes in adult mouse models.
Bosso G, Cintra Herpst AC, Laguía O, Adetchessi S, Serrano R, Blasco MA. Bosso G, et al. Cell Death Differ. 2024 Jun;31(6):804-819. doi: 10.1038/s41418-024-01300-x. Epub 2024 May 2. Cell Death Differ. 2024. PMID: 38698060 Free PMC article. - Integrated analysis of EREG expression, a gene associated with cervical cancer prognosis.
Yang S, Yang X, Li C. Yang S, et al. Am J Cancer Res. 2023 Oct 15;13(10):4644-4660. eCollection 2023. Am J Cancer Res. 2023. PMID: 37970371 Free PMC article. - BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature.
Guerrero P, Albarrán V, San Román M, González-Merino C, García de Quevedo C, Moreno J, Calvo JC, González G, Orejana I, Chamorro J, Martínez-Delfrade Í, Morón B, de Frutos B, Ferreiro MR. Guerrero P, et al. Cancers (Basel). 2023 Oct 31;15(21):5243. doi: 10.3390/cancers15215243. Cancers (Basel). 2023. PMID: 37958416 Free PMC article. Review. - Investigation of evolutionary dynamics for drug resistance in 3D spheroid model system using cellular barcoding technology.
Yalcin GD, Yilmaz KC, Dilber T, Acar A. Yalcin GD, et al. PLoS One. 2023 Sep 26;18(9):e0291942. doi: 10.1371/journal.pone.0291942. eCollection 2023. PLoS One. 2023. PMID: 37751451 Free PMC article. - Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022.
Singh AK, Sonawane P, Kumar A, Singh H, Naumovich V, Pathak P, Grishina M, Khalilullah H, Jaremko M, Emwas AH, Verma A, Kumar P. Singh AK, et al. ACS Omega. 2023 Jul 26;8(31):27819-27844. doi: 10.1021/acsomega.3c00332. eCollection 2023 Aug 8. ACS Omega. 2023. PMID: 37576670 Free PMC article. Review.
References
- Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin 2017; 67: 177–193. - PubMed
- Joyce T, Oikonomou E, Kosmidou V, et al. A molecular signature for oncogenic BRAF in human colon cancer cells is revealed by microarray analysis. Curr Cancer Drug Targets 2012; 12: 873–898. - PubMed
- Popovici V, Budinska E, Tejpar S, et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol 2012; 30: 1288–1295. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous